Nidogen-1, a Player in KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.

ABSTRACT: Despite advances in outcome, one third of children with acute myeloid leukemia (AML) relapse, and less than half will achieve long-term survival. Relapse in AML has been shown to be driven in part by leukemic stem cells (LSCs), highlighting the unmet medical need to better characterize and target this therapy-resistant cell population. Micro-array profiling of pediatric AML subpopulations (LSCs and leukemic myeloblasts) and their healthy counterparts revealed nidogen-1 (NID1) as expressed in both leukemic subpopulations while absent in the hematopoietic stem cell. Using the TARGET dataset including pediatric AML patients (n = 1025), NID1 expression showed a correlation with worse event-free survival and KMT2A rearrangements. Drug response profiling of a NID1 knockdown model demonstr

SUBMITTER: Vanhooren J 

PROVIDER: S-EPMC11988693 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature